June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Effect of intravitreal ranibizumab injection on eyes with refractory diabetic macular edema after sub-Tenon capsule triamcinolone acetonide injection
Author Affiliations & Notes
  • Takayuki Koike
    Chiba University Hospital, Chiba, Japan
  • Footnotes
    Commercial Relationships Takayuki Koike, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1752. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Takayuki Koike; Effect of intravitreal ranibizumab injection on eyes with refractory diabetic macular edema after sub-Tenon capsule triamcinolone acetonide injection. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1752.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine the effect of intravitreal ranibizumab (IVR) on refractory diabetic macular edema (DME) after sub-Tenon capsule triamcinolone acetonide (STTA) injection.

Methods: This was a retrospective review of the medical records of 14 eyes of 11 patients with refractory DME after STTA. All eyes received intravitreal IVR between March 2014 and July 2014. The main outcome measurements were the best-corrected visual acuity (BCVA) and central macular thickness (CMT) measured by optical coherence tomography (OCT) before and after IVR. The followed-up period was three months. The statistical analyses were performed by paired t tests. A P<0.05 was considered significant.

Results: The mean age was 64.8±12.4 years. Two eyes (14.2%) were pseudophakic eyes, 9 eyes (64.3%) had a history of pan-retinal photocoagulation, 4 eyes (28.5%) had partial photocoagulation, 10 eyes (71.4%) had microaneurysm photocoagulation, 2 eyes (14.2%) had subthreshold micropulse diode laser photocoagulation, and one eye (7.1%) had vitrectomy before the IVR. The mean BCVA was 0.382±0.20 logMAR units before STTA and 0.432±0.30 logMAR unit after STTA(P=0.5158). The mean BCVA was 0.408±0.29 logMAR units before and 0.354±0.22 logMAR units after the IVR (P=0.1285). The mean CMT was 526.20±90.57μm before STTA and 563.41±188.17 μm after STTA (P=0.6373). The mean CMT was 560.57±182.13 μm before IVR and 424.85±128.97μm after IVR (P=0.0222).

Conclusions: IVR can be a therapeutic option for refractory DME after STTA injection.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×